ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A.
about
Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A.Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.Recombinant factor VIII in the management of hemophilia A: current use and future promise.Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies.Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.Novel coagulation factor concentrates: issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients.Elucidation of Factor VIII Activity Pharmacokinetics: A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa.Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit.Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A.Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A.Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.Clinical observation on safety and efficacy of a plasma- and albumin-free recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A.Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study.Pharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance?Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A.Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice.Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies.Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.Assessment of relative bioavailability of two presentations of moroctocog alfa (AF-CC) in subjects with moderately severe or severe hemophilia A.Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia A.
P2860
Q34283156-49D92142-393F-42E2-9DD6-D0485A64D313Q35778288-DB5BCB53-36C0-42E7-A382-C8F534F3822EQ36912731-460D4365-140A-4056-941D-B4B88CC9DFC4Q37230340-45B04F33-EDAA-41E6-8DCB-B16F839575B1Q37976470-27189DC4-E877-4E30-993A-994786044A5AQ38008021-6EF93385-CA3A-4A29-9F9E-2C3504523081Q38079624-5FE11CC2-7A7B-4009-B43A-50594D64324FQ38822601-FF6488CE-B79C-4C72-BFF4-D4DCEBC8EB06Q38950839-FBAF9B7B-17D5-4493-B607-9AA925BF0239Q39074627-F92B8D87-F388-42C2-BD0B-082E0EECE6CFQ39475869-2E66D4B5-C210-40A6-9164-0C94839DFC65Q41975229-155BF178-33F2-474A-B333-A8A347ABE8B9Q43684691-EDDA72EB-EBD2-4597-8477-6944F9D381DAQ45863724-8EEB33EF-F2C5-414A-A581-A866C571CA33Q45869044-A6A5A503-59B8-4368-85EC-1D4815026BB0Q45869919-40E3F258-FD5B-4F8B-9546-7CFA154034E2Q45871529-1AE7D8F2-D7EF-4BF5-94C7-FEEE8AFCB8F6Q45871898-50ACC63E-4B17-4557-BAC5-150CBED944E7Q45872547-9B95D84E-4DFC-4F10-8BD7-68C8C399480FQ45874491-DEE04D2D-3623-430D-8556-88F797375FC6Q45885625-E7088AA8-EF14-4B75-92D0-0EA557338F16Q53835196-5C87C160-2C66-43D9-8A9B-00B255C0E6AD
P2860
ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
ReFacto and Advate: a single-d ...... n subjects with haemophilia A.
@en
ReFacto and Advate: a single-d ...... n subjects with haemophilia A.
@nl
type
label
ReFacto and Advate: a single-d ...... n subjects with haemophilia A.
@en
ReFacto and Advate: a single-d ...... n subjects with haemophilia A.
@nl
prefLabel
ReFacto and Advate: a single-d ...... n subjects with haemophilia A.
@en
ReFacto and Advate: a single-d ...... n subjects with haemophilia A.
@nl
P2093
P2860
P1433
P1476
ReFacto and Advate: a single-d ...... n subjects with haemophilia A.
@en
P2093
C Rothschild
H Pollmann
J Di Paola
J Feingold
P2860
P304
P356
10.1111/J.1365-2516.2006.01420.X
P577
2007-03-01T00:00:00Z